TEANECK, N.J., July 24, 2017 -- The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on September 27, 2017, to stockholders of record at the close of business on September 6, 2017.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. For further information, please visit www.pahc.com.
Contact: Richard Johnson Chief Financial Officer, Phibro Animal Health Corporation +1 201-329-7300 [email protected]


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Washington Post Publisher Will Lewis Steps Down After Layoffs
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



